Variability in Response to Anti-Rheumatic Drugs

Edited by
P.M. Brooks
R.O. Day
G.G. Graham
K.M. Williams

Birkhäuser Verlag
Basel · Boston · Berlin
Contents

Preface ....................................................... IX

NON-STEROIDAL ANTI-INFLAMMATORY DRUGS

R.O. Day
Variability in response to NSAIDs: What progress? ........................................ 3

P. Seideman
Paracetamol in rheumatoid arthritis .......................................................... 7

Stereochemical Contributions to Variability in Response to NSAIDs

K.M. Williams
Chiral NSAIDs: So what? ....................................................... 15

S. Menzel-Soglowek, G. Geisslinger and K. Brune
Metabolic chiral inversion of 2-arylpropionates in different tumor cell lines .......... 23

G. Geisslinger, S. Menzel-Soglowek and K. Brune
(R)-Flurbiprofen: isomeric ballast or active entity of the racemic compound .......... 31

Further Factors Leading to Variability in Response to NSAIDs

K.D. Rainsford
Mechanisms of NSAIDs on joint destruction in osteoarthritis .......................... 39

Pharmacokinetics and pharmacodynamics of non-steroidal anti-inflammatory drugs in synovial fluid ................................................................. 45

K. Brune, B. Nuernberg and H.T. Schneider
Biliary elimination of aspirin after oral and intravenous administration in patients . 51

K.D. Rainsford
Mechanisms of gastrointestinal damage by NSAIDs .......................................... 59

TRIALS AND TRIAL DESIGN

T. Pincus and L.F. Callahan
Variability in individual responses of 532 patients with rheumatoid arthritis to first-line and second-line drugs ....................................................... 67
M.H. Liang and R.B. Brigham
Towards more informative pilot studies with new anti-rheumatic drugs .................................. 77

T. Pincus
Limitations to standard randomized controlled clinical trials to evaluate combination therapies in rheumatic diseases ......................................................... 83

COMBINATION THERAPY

P.M. Brooks
Combination therapy in rheumatoid arthritis ................................................................. 95

M. Nobunaga and M. Yasuda
Comparison of clinical effects of bucillamine between additive combination and single administration study in rheumatoid arthritis ............................................. 105

DISEASE MODIFYING ANTI-RHEUMATIC DRUGS

Mode of action of DMARDs

A.C. Allison and R.V. Waters
Long-acting anti-rheumatic drugs induce differentiation of cells of the monocyte-macrophage lineage and alter the expression of cytokines and IL-1 receptor antagonist . 113

Methotrexate and Antimalarials

D.E. Furst
Methotrexate: New mechanisms and old toxicities ................................................. 131

D.J. Cutler
Possible mechanisms of action of antimalarials in rheumatic disease .................. 139

S. Tett, A. McLachlan, R.O. Day and D.J. Cutler
Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine . 145

R.I. Rynes
Toxicity of antimalarial drugs in rheumatoid arthritis ................................................. 151

DMARDs: New and Old

P.M. Brooks
Tenidap: A new antiarthritic agent ................................................................. 161

A.C. Allison and E.M. Eugui
Immunosuppressive and other anti-rheumatic activities of mycophenolate mofetil . 165
M.J. Parnham and D.R. Blake
Antioxidants as anti-rheumatics ........................................... 189

M. Dougados
Sulphasalazine in rheumatic diseases ....................................... 197

D.A. Joyce
Variability in response to D-penicillamine: pharmacokinetic insights ..................................................... 203

G.G. Graham, J.B. Ziegler and G.D. Champion
Medicinal chemistry of gold .................................................. 209

Comparative effects of gold on the interactions of transcription factors with DNA .............................................. 219

Subject Index ............................................................................. 225